Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-4-14
pubmed:abstractText
Congenital heart block (CHB) is presumed to be caused by transplacental passage of maternal immunoglobulin against Ro and La ribonucleoproteins. The recurrence rate in subsequent pregnancies following the birth of a child with CHB is approximately 19%. The purpose of this study was to determine whether intravenous immunoglobulin (IVIG) therapy could prevent the development of CHB in the fetuses of high-risk pregnant women.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
1529-0131
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1147-52
pubmed:meshHeading
pubmed-meshheading:20131278-Autoantigens, pubmed-meshheading:20131278-Continental Population Groups, pubmed-meshheading:20131278-Dexamethasone, pubmed-meshheading:20131278-Drug Therapy, Combination, pubmed-meshheading:20131278-Female, pubmed-meshheading:20131278-Heart Block, pubmed-meshheading:20131278-Heart Defects, Congenital, pubmed-meshheading:20131278-Humans, pubmed-meshheading:20131278-Hydroxychloroquine, pubmed-meshheading:20131278-Immunoglobulins, Intravenous, pubmed-meshheading:20131278-Infant, pubmed-meshheading:20131278-Infant, Newborn, pubmed-meshheading:20131278-Prednisone, pubmed-meshheading:20131278-Pregnancy, pubmed-meshheading:20131278-Prospective Studies, pubmed-meshheading:20131278-Recurrence, pubmed-meshheading:20131278-Ribonucleoproteins, pubmed-meshheading:20131278-Treatment Failure
pubmed:year
2010
pubmed:articleTitle
Failure of intravenous immunoglobulin to prevent congenital heart block: Findings of a multicenter, prospective, observational study.
pubmed:affiliation
St. Thomas' Hospital, and King's College London, London, UK. ceciliapisoni@gmail.com
pubmed:publicationType
Journal Article, Multicenter Study